ClinConnect ClinConnect Logo
Search / Trial NCT00002531

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Launched by JOHANN WOLFGANG GOETHE UNIVERSITY HOSPITAL · Feb 13, 2004

Trial Information

Current as of July 15, 2025

Unknown status

Keywords

Untreated Adult Acute Lymphoblastic Leukemia T Cell Adult Acute Lymphoblastic Leukemia B Cell Adult Acute Lymphoblastic Leukemia Non T, Non B Adult Acute Lymphoblastic Leukemia

ClinConnect Summary

OBJECTIVES: I. Develop risk-adapted therapy for patients with low-risk, high-risk, T-cell, or B-cell acute lymphocytic leukemia (ALL). II. Determine the complete remission rate in these patients treated with the following strategies: increased doses of cyclophosphamide during induction and reinduction, early use of high-dose cytarabine plus mitoxantrone (for high-risk patients), and increased doses of methotrexate (for B-cell ALL patients). III. Determine the duration of remission and survival of patients in all risk groups treated with intensified consolidation and subtype-specific chemoth...

Gender

ALL

Eligibility criteria

  • DISEASE CHARACTERISTICS: Diagnosis of low-risk acute lymphocytic leukemia (ALL) (common ALL or pre-B-cell) Must meet 1 of the following 2 conditions: Age 51 to 65 and meets the following criteria: No mediastinal mass No T-cell or B-cell disease Age 15 to 50 and meets the following criteria: Philadelphia chromosome (Ph) negative bcr-abl negative Initial WBC less than 30,000/mm3 OR Diagnosis of T-cell ALL with or without mediastinal involvement Age 15 to 50 OR Diagnosis of high-risk ALL (common ALL or pre-B-cell) Age 15 to 50 and meets 1 of the following criteria: Ph positive bcr-abl positive Pre-pre-B-cell disease, i.e., t(4;11) Initial WBC greater than 30,000/mm3 OR Diagnosis of B-cell ALL
  • PATIENT CHARACTERISTICS: Age: See Disease Characteristics 15 to 65 Performance status: Not specified Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: No renal failure Cardiovascular: No cardiomyopathy Other: HIV-1 and HIV-2 negative No severe psychiatric disease
  • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior cytostatic drugs except vincristine Endocrine therapy: Prior corticosteroids allowed Radiotherapy: Not specified Surgery: Not specified Other: No more than 2 weeks of prior therapy No other prior cytostatic drugs

About Johann Wolfgang Goethe University Hospital

Johann Wolfgang Goethe University Hospital, located in Frankfurt am Main, Germany, is a prominent academic medical center affiliated with Goethe University. Renowned for its commitment to advancing healthcare through innovative research and clinical excellence, the hospital serves as a vital hub for clinical trials and medical studies. It integrates cutting-edge technology with a multidisciplinary approach, facilitating collaboration among healthcare professionals to enhance patient outcomes. The hospital is dedicated to ethical research practices and adheres to stringent regulatory standards, ensuring the safety and well-being of trial participants while contributing to the advancement of medical science.

Locations

Frankfurt, , Germany

Patients applied

0 patients applied

Trial Officials

Dieter Hoelzer, MD, PhD

Study Chair

Johann Wolfgang Goethe University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials